Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial (English)
- New search for: Rulli, E.
- New search for: Marabese, M.
- New search for: Torri, V.
- New search for: Farina, G.
- New search for: Veronese, S.
- New search for: Bettini, A.
- New search for: Longo, F.
- New search for: Moscetti, L.
- New search for: Ganzinelli, M.
- New search for: Lauricella, C.
- New search for: Rulli, E.
- New search for: Marabese, M.
- New search for: Torri, V.
- New search for: Farina, G.
- New search for: Veronese, S.
- New search for: Bettini, A.
- New search for: Longo, F.
- New search for: Moscetti, L.
- New search for: Ganzinelli, M.
- New search for: Lauricella, C.
In:
ANNALS OF ONCOLOGY
;
26
, 10
;
2079-2084
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
-
Contributors:Rulli, E. ( author ) / Marabese, M. ( author ) / Torri, V. ( author ) / Farina, G. ( author ) / Veronese, S. ( author ) / Bettini, A. ( author ) / Longo, F. ( author ) / Moscetti, L. ( author ) / Ganzinelli, M. ( author ) / Lauricella, C. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 26, 10 ; 2079-2084
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:6 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26, Issue 10
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 2007
-
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET…Scagliotti, G. V. / Di Maio, M. et al. | 2015
- 2010
-
Academically led clinical trials: challenges and opportunitiesTurajlic, S. / Larkin, J. / Swanton, C. et al. | 2015
- 2012
-
Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteriaHeller, G. et al. | 2015
- 2017
-
Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and managementMcLellan, B. / Ciardiello, F. / Lacouture, M. E. / Segaert, S. / Van Cutsem, E. et al. | 2015
- 2026
-
The new therapeutical scenario of Hodgkin lymphomaStathis, A. / Younes, A. et al. | 2015
- 2034
-
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatmentsLedermann, J. A. / Canevari, S. / Thigpen, T. et al. | 2015
- 2044
-
Treatment of mCRPC in the AR-axis-targeted therapy-resistant stateChi, K. / Hotte, S. J. / Joshua, A. M. / North, S. / Wyatt, A. W. / Collins, L. L. / Saad, F. et al. | 2015
- 2057
-
BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significanceEccles, D. M. / Mitchell, G. / Monteiro, A. N. / Schmutzler, R. / Couch, F. J. / Spurdle, A. B. / Gómez-García, E. B. et al. | 2015
- 2066
-
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)Yoshioka, H. / Azuma, K. / Yamamoto, N. / Takahashi, T. / Nishio, M. / Katakami, N. / Ahn, M. J. / Hirashima, T. / Maemondo, M. / Kim, S. W. et al. | 2015
- 2073
-
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patientsPlanchard, D. / Loriot, Y. / André, F. / Gobert, A. / Auger, N. / Lacroix, L. / Soria, J. C. et al. | 2015
- 2079
-
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialRulli, E. / Marabese, M. / Torri, V. / Farina, G. / Veronese, S. / Bettini, A. / Longo, F. / Moscetti, L. / Ganzinelli, M. / Lauricella, C. et al. | 2015
- 2085
-
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patientsVan Cutsem, E. / Prenen, H. / D'Haens, G. / Bennouna, J. / Carrato, A. / Ducreux, M. / Bouché, O. / Sobrero, A. / Latini, L. / Staines, H. et al. | 2015
- 2092
-
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisCremolini, C. / Di Bartolomeo, M. / Amatu, A. / Antoniotti, C. / Moretto, R. / Berenato, R. / Perrone, F. / Tamborini, E. / Aprile, G. / Lonardi, S. et al. | 2015
- 2097
-
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)Ryu, M. H. / Baba, E. / Lee, K. H. / Park, Y. I. / Boku, N. / Hyodo, I. / Nam, B. H. / Esaki, T. / Yoo, C. / Ryoo, B. Y. et al. | 2015
- 2102
-
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancerJiang, D. M. / Raissouni, S. / Mercer, J. / Kumar, A. / Goodwin, R. / Heng, D. Y. / Tang, P. A. / Doll, C. / MacLean, A. / Powell, E. et al. | 2015
- 2107
-
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisBracarda, S. / Iacovelli, R. / Boni, L. / Rizzo, M. / Derosa, L. / Rossi, M. / Galli, L. / Procopio, G. / Sisani, M. / Longo, F. et al. | 2015
- 2113
-
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial designGerety, E. L. / Lawrence, E. M. / Wason, J. / Yan, H. / Hilborne, S. / Buscombe, J. / Cheow, H. K. / Shaw, A. S. / Bird, N. / Fife, K. et al. | 2015
- 2119
-
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) studyLibé, R. / Borget, I. / Ronchi, C. L. / Zaggia, B. / Kroiss, M. / Kerkhofs, T. / Bertherat, J. / Volante, M. / Quinkler, M. / Chabre, O. et al. | 2015
- 2125
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsNieto, Y. / Tu, S. M. / Bassett, R. / Jones, R. B. / Gulbis, A. M. / Tannir, N. / Kingham, A. / Ledesma, C. / Margolin, K. / Holmberg, L. et al. | 2015
- 2133
-
Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factorsSprauten, M. / Haugnes, H. S. / Brydøy, M. / Kiserud, C. / Tandstad, T. / Bjøro, T. / Bjerner, J. / Cvancarova, M. / Fosså, S. D. / Oldenburg, J. et al. | 2015
- 2141
-
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancerDijkgraaf, E. M. / Santegoets, S. J. / Reyners, A. K. / Goedemans, R. / Wouters, M. C. / Kenter, G. G. / van Erkel, A. R. / van Poelgeest, M. I. / Nijman, H. W. / van der Hoeven, J. J. et al. | 2015
- 2149
-
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trialUeda, T. / Morioka, H. / Nishida, Y. / Kakunaga, S. / Tsuchiya, H. / Matsumoto, Y. / Asami, Y. / Inoue, T. / Yoneda, T. et al. | 2015
- 2155
-
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS riskSpina, M. / Nagy, Z. / Ribera, J. M. / Federico, M. / Aurer, I. / Jordan, K. / Borsaru, G. / Pristupa, A. S. / Bosi, A. / Grosicki, S. et al. | 2015
- 2161
-
Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?Ning, J. / Peng, S. / Ueno, N. / Xu, Y. / Shih, Y. / Karuturi, M. / Giordano, S. / Shen, Y. et al. | 2015
- 2168
-
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†Bompas, E. / Le Cesne, A. / Tresch-Bruneel, E. / Lebellec, L. / Laurence, V. / Collard, O. / Saada-Bouzid, E. / Isambert, N. / Blay, J. Y. / Amela, E. Y. et al. | 2015
- 2173
-
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaMiddleton, M. R. / Friedlander, P. / Hamid, O. / Daud, A. / Plummer, R. / Falotico, N. / Chyla, B. / Jiang, F. / McKeegan, E. / Mostafa, N. M. et al. | 2015
- 2180
-
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer modelMaia, A. R. / de Man, J. / Boon, U. / Janssen, A. / Song, J. Y. / Omerzu, M. / Sterrenburg, J. G. / Prinsen, M. B. / Willemsen-Seegers, N. / de Roos, J. A. et al. | 2015
- 2193
-
Health care in the United States—basic human right or entitlement?Jones, G. H. / Kantarjian, H. et al. | 2015
- 2196
-
Reply to the letter to the editor ‘Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy’ by Siva et al.de Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 2196
-
Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapySiva, S. / Senan, S. / Ball, D. et al. | 2015
- 2197
-
Primum non nocereTempleton, A. J. / Šeruga, B. et al. | 2015
- 2198
-
Reply to letter to the editor ‘Primum non nocere’ by Templeton and ŠerugaAapro, M. / Moebus, V. / Nitz, U. / O'Shaughnessy, J. / Pronzato, P. / Untch, M. / Tomita, D. / Bohac, C. / Leyland-Jones, B. et al. | 2015
- 2199
-
MiR-29c downregulation contributes to metastatic progression in colorectal cancerCristóbal, I. / Madoz-Gúrpide, J. / Manso, R. / Rojo, F. / García-Foncillas, J. et al. | 2015
- 2199
-
Reply to the letter to the editor ‘Flaws in the trial design of IFCT-0802’ by Gyawali et al.Pujol, J. L. / Morin, F. / Zalcman, G. et al. | 2015
- 2200
-
Reply to the letter to the editor ‘Journey to a faraway land’ by Alkan et al.Hartkopf, A. D. / Brucker, S. Y. / Taran, F. A. et al. | 2015
- 2200
-
Journey to a faraway landAlkan, A. / Karcı, E. / Utkan, G. et al. | 2015